The NUVISAN group acquires a pre-clinical unit in Grafing from Merck

New Managing Director at the Grafing site

01-Jul-2016 - Germany

NUVISAN acquires a research and development site in Grafing, Germany from its longstanding partner Merck. With the addition ofpre-clinical DMPK Services from Merck, NUVISAN passes the next phase in its realignment as a pre-clinical and clinical contract research organization (CRO).

NUVISAN particularly intends to reach out to globally operating customers, through integration of activities at its three locations and the offering of an even wider variety of services. On the other hand Merck continues to have access to the extensive experience of the 40 staff members at Grafing by way of a longstanding partnership. Merck will continue to make use of the site’s core competencies for research activities.

By expanding its core competencies to include in-vitro and in-vivo DMPK (Drug Metabolism and Pharmacokinetics) as well as radioisotope syntheses, the NUVISAN group aims to develop as a leading full-service CRO under the banner ‘All Services under One Roof’. Currently, the group’s areas of focus are bioanalysis, biopharmaceutical analysis, biomarkers, pharmaceutical analysis, Clinical Pharmacology trials and Clinical Trial Supplies.

As a fully integrated provider of pre-clinical studies examining the absorption, distribution, metabolism and excretion of drugs, NUVISAN Pharma Grafing can now offer its customers the capability to explore important aspects regarding the safety and effectiveness of their products before initiating first in human trials at the NUVISAN clinical research unit in Neu-Ulm.

NUVISAN Pharma GmbH Grafing’s Managing Director from 1st July 2016 will be Dr. Michael Gassen. Under his direction, there will be further expansion particularly in the rapidly growing sector of in vitro & in vivo DMPK studies. "With the takeover of Merck’s Institute of pharmacokinetics and metabolism, our range of services is complete," said Dr. Gassen. "We can now offer the entire supply chain of DMPK studies starting with enzymes and cells going right through to clinical trials."

Dr. Gassen is a recognized expert in the field of Drug Metabolism and Pharmacokinetics. A PhD chemist with more than20 years of experience in pharmaceutical research and development with research-based pharmaceutical companies and CROs. He was most recently Global Head of Metabolism and Environmental Fate at the global CRO Harlan Laboratories (now part of Envigo), responsible for the entire area of drug metabolism

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances